Accuray (NASDAQ:ARAY) Issues Quarterly Earnings Results, Beats Expectations By $0.03 EPS

Accuray (NASDAQ:ARAY) posted its quarterly earnings data on Wednesday. The medical equipment provider reported $0.02 earnings per share for the quarter, topping the consensus estimate of ($0.01) by $0.03, Zacks reports. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%.

Accuray Price Performance

Accuray stock traded up $0.16 during midday trading on Wednesday, reaching $2.49. The company’s stock had a trading volume of 1,589,761 shares, compared to its average volume of 671,667. The stock has a market cap of $250.42 million, a PE ratio of -14.65 and a beta of 1.51. The company has a current ratio of 1.63, a quick ratio of 0.87 and a debt-to-equity ratio of 3.59. Accuray has a 52 week low of $1.40 and a 52 week high of $2.95. The business has a 50-day moving average price of $2.09 and a 200-day moving average price of $1.96.

Analysts Set New Price Targets

Separately, StockNews.com cut shares of Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.